KYTX Earnings & Financial Statements
Kyverna Therapeutics, Inc.
$5.69
-$0.08(-1.47%)
30
Overall
60
Value
10
Tech
21
Quality
Market Cap
$351.58M
Volume
1.28M
52W Range
$5.96 - $13.67
Target Price
$30.40
KYTX earnings and financial statements: Kyverna Therapeutics, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
KYTX Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | - | - | - | $7.03M | - |
| Operating income | -$169.83M | -$142.60M | -$62.41M | -$29.38M | - |
| EBITDA | -$159.02M | -$125.20M | -$58.47M | - | - |
| Net income | -$161.31M | -$127.48M | -$60.37M | -$28.89M | - |
| EPS (diluted) | $-3.64 | $-3.33 | $-89.61 | $-63.43 | - |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $293.83M | $304.64M | $75.19M | $66.92M | - |
| Total liabilities | $61.55M | $38.06M | $26.02M | $20.25M | - |
| Shareholders’ equity | $232.28M | $266.59M | -$131.40M | -$74.00M | - |
| Cash and equivalents | $124.09M | $96.62M | $34.65M | $37.73M | - |
| Long-term debt | $25.06M | $4.30M | $6.16M | $8.29M | - |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$153.70M | -$114.30M | -$52.41M | -$36.11M | - |
| Capital expenditure | -$1.06M | -$2.21M | - | - | - |
| Free cash flow | -$154.83M | -$116.50M | -$53.03M | -$36.88M | -$23.44M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | KYTX | $5.69 | -1.5% | 1.28M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Kyverna Therapeutics, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW